Shares of BioNTech SE (BNTX) are soaring over 50% in pre-market today, after the company announced rapid progress on COVID-19 vaccine program to address global public health threat. The company's product candidate, BNT162, is a potential first-in-class mRNA vaccine in the worldwide effort against COVID-19.
BioNTech intends to initiate clinical testing for BNT162 in late April 2020, subject to regulatory approval, as part of a global clinical development program in Europe (commencing in Germany), the United States and China.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.